Current findings for Likeness Rx
Compare the tirzepatide subscription choices
Tirzepatide subscriptions are listed at $199 for one month, $477 for three, $834 for six and $1,548 for twelve. The annual equivalent is $129 per month. Tell the clinician about previous treatment; the advertised term is a financial choice, not a dose or restart instruction.
Sources: Likeness Rx — GLP-1 weight care
Four terms, rather than one universal monthly bill
For semaglutide, the page lists $139 for one month, $327 for three months, $534 for six months and $948 for twelve months. The longer-term monthly equivalents are $109, $89 and $79. For tirzepatide, the corresponding totals are $199, $477, $834 and $1,548, with longer-term equivalents of $159, $139 and $129.
The lowest equivalent therefore comes with the longest payment term. Keep the full amount due beside the selected term when comparing another provider’s monthly offer. A lower equivalent does not mean that only that number will be charged today.
Sources: Likeness Rx — GLP-1 weight care
The subscription’s next charge deserves its own check
Likeness says the chosen term renews automatically. Its page also describes the first refill being billed early so the pharmacy can process the prescription before supply runs out. Ask for the actual next charge date rather than calculating it from the delivery date.
The page says patients can change, pause or cancel a plan. Confirm the cutoff, the steps and whether a pending prescription has entered fulfillment. Save confirmation that a cancellation was processed; stopping the next term is different from reversing an order already dispensed.
Sources: Likeness Rx — GLP-1 weight care
What the provider says is included
The offer lists an online provider visit, medication at standard doses, supplies, shipping and ongoing messaging. It describes a health questionnaire and licensed provider assessment before prescribing, followed by fulfillment through a US pharmacy. We have not tested those services or verified the assigned pharmacy.
Ask who handles dose questions, how a refill is approved and what contact route reaches the clinician or pharmacist. A payment-support conversation cannot determine the medical instructions for a prescription.
Sources: Likeness Rx — GLP-1 weight care
Eligibility, refunds and preparation
The page states that a patient whose provider declines a prescription receives an automatic refund. That eligibility promise should be distinguished from refund conditions after dispensing. The page also advertises HSA/FSA acceptance; confirm the specific payment arrangement.
The reviewed products are compounded injections. They are not approved Wegovy, Ozempic, Zepbound or Mounjaro products. Identify the actual preparation, quantity and pharmacy, and discuss the individual medical rationale with the clinician.
Sources: Likeness Rx — GLP-1 weight care · FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
Tirzepatide: what the name does and does not tell you
Zepbound and Mounjaro contain tirzepatide, a medicine that activates GIP and GLP-1 receptors. Zepbound is labeled for weight reduction and long-term maintenance in eligible adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is labeled for type 2 diabetes in adults and children aged 10 years and older, and for reducing major cardiovascular events in adults with type 2 diabetes who are at high risk for these events. Those uses do not make Mounjaro an FDA-approved weight-management brand.
The approved products are injections. A compounded tirzepatide tablet or dissolvable preparation is not FDA-approved Zepbound or Mounjaro; their clinical results do not validate that alternative formulation. Ask for the exact drug, route, ingredients, and dispensing pharmacy. This page’s medication-specific URL does not confirm that Likeness Rx currently offers it.
Sources: Zepbound prescribing information · Mounjaro prescribing information
Compounded medicines are not FDA-approved. FDA recommends them only when a patient’s medical needs cannot be met by an approved medicine. Its April 2026 update says semaglutide and tirzepatide are not on the drug shortage list or the 503B bulks list. Patient-specific exceptions and other legal conditions matter; a “personalized” label, vitamin additive, or pharmacy registration does not by itself establish compliance or effectiveness.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA · FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
Safety questions for the prescribing clinician
The approved products cited here have a boxed warning about thyroid C-cell tumors in rodents; whether they cause these tumors in humans is unknown. Their contraindications include a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and specified serious allergic reactions. These are specific conditions, rather than a statement that every thyroid disorder rules out treatment. Review the exact product label with your clinician.
Tell the clinician about severe stomach-emptying problems, pancreatitis or gallbladder history, kidney concerns, diabetic eye disease, and every medicine or supplement you use. The labels do not recommend these products in severe gastroparesis. Insulin and medicines such as sulfonylureas can increase low-blood-sugar risk when used with them; adjustments belong with the prescriber. These examples do not replace the full safety review.
Zepbound should be discontinued when pregnancy is recognized. Tirzepatide can reduce the effectiveness of oral hormonal contraceptives: the Zepbound and Mounjaro labels advise a non-oral method or an added barrier method for four weeks after starting and for four weeks after each dose increase. Ask the clinician about pregnancy planning and breastfeeding for the exact prescription.
Sources: Zepbound prescribing information · Mounjaro prescribing information
Severe abdominal pain that does not go away, with or without vomiting, can be a pancreatitis warning; the labels instruct patients to stop the medicine and seek medical help promptly. Repeated vomiting or inability to keep fluids down also needs prompt assessment. For trouble breathing or swallowing, swelling of the face, tongue or throat, or collapse suggesting a serious allergic reaction, call 911 or your local emergency number immediately. Your provider should explain urgent and after-hours care before treatment starts.
Sources: Zepbound prescribing information · Mounjaro prescribing information · Anaphylaxis: MedlinePlus Medical Encyclopedia
Tell the anesthesia or procedure team about treatment before surgery or deep sedation. Do not independently combine GLP-1 products, shorten injection intervals or restart an old high dose after a break. Procedure planning and side effects and warning symptoms explain the questions to resolve with the care team.
Sources: Zepbound prescribing information · Mounjaro prescribing information
Questions to resolve before paying Likeness Rx
- What is the total charge for the term I select, and when is the first refill billed?
- How far before renewal must a cancellation be completed?
- Which clinician and dispensing pharmacy would handle my prescription?
- Which refund conditions apply before assessment, after approval and after dispensing?
Ask for a written quote showing the medication, care or membership fee, labs, shipping, supplies, first payment, renewal payment, and cancellation cutoff. A monthly equivalent on a prepaid plan is different from paying that amount every month. A four-week supply and a calendar-month subscription also have different annual totals.
Verify your prescriber’s license and the dispensing pharmacy with the relevant state boards. Check that the pharmacy named on your prescription matches the pharmacy on the package. If injectable medication arrives warm or inadequately refrigerated, FDA advises against using it; contact the dispensing pharmacy for instructions. Avoid products sold as research chemicals or without a prescription.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
How to use this profile
This is a review of public information, not a hands-on clinical test or a verified patient review. We do not assign star ratings to clinical care, medication quality, response time, or shipping. An advertised benefit remains a provider claim unless independent evidence supports the specific claim. Confirm current availability, state eligibility, and the final terms directly before enrolling.
Read our source and correction policy and commercial disclosure. Medical review has not been completed.